The effect of Tamsulosin and Solifenacin in the treatment of double J stent-related urinary symptoms

Comparison of the effect of Tamsulosin, Solifenacin and their combination in the treatment of double J stent-related urinary symptoms in patients with ureteral stones

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200831048564N1

Enrollment

Registered

2020-09-17

Start date

2019-09-23

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lower urinary tract symptoms, ureteral stone. Urinary calculus, unspecified

Interventions

Intervention 1: Intervention group: 1

cap Tamsulosin 0.4 mg once daily for 2 weeks. Intervention 2: Intervention group: 2

Tab Solifenacin 5 mg once daily for 2 weeks. Intervention 3: Intervention group:3, cap including Tamsulosin 0.4 mg + Solifenacin 5 mg, once daily for 2 weeks. Intervention 4: Control group:Tab Placebo

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: patients with ureteral stones undergoing unilateral transurethral lithotripsy

Exclusion criteria

Exclusion criteria: History of surgery on the urinary system Performing urethroscopy or double j implantation bilaterally History of LUTS symptoms following BPH Other diseases of the urinary system such as neurogenic bladder and overactive bladder Concomitant use of anti-adrenergic and anticholinergic drugs pregnancy Drug Allergy Occurrence of major complications following surgery

Design outcomes

Primary

Measure	Time frame
Ureteral stent urinary symptoms. Timepoint: 2 weeks after intervention. Method of measurement: Based on Ureteral Stent Symptoms Questionnaire (USSQ).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Alireza Akhavan Rezayat

Mashhad University of Medical Sciences

akhavara@mums.ac.ir+98 51 3840 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026